Alzinova (ALZ SS)

Alzinova AB is a Swedish clinical-stage biopharma company that develops immunotherapies for the treatment of Alzheimer's disease. Its lead product candidate is ALZ-101, a therapeutic vaccine for Alzheimer's that has completed a phase 1b study. The company is also developing ALZ-201, a monoclonal antibody that targets and neutralizes the neurotoxic forms of the peptide Aß42, known as oligomers, which are considered a primary cause of Alzheimer's disease.